Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Carbidopa, (r)-isomer
2. Carbidopa, (s)-isomer
3. Lodosin
4. Lodosyn
5. Methyldopahydrazine
6. Mk 485
7. Mk 486
8. Mk-485
9. Mk-486
10. Mk485
11. Mk486
1. 28860-95-9
2. Lodosyn
3. Carbidopa Anhydrous
4. (s)-(-)-carbidopa
5. (s)-carbidopa
6. S-(-)-carbidopa
7. Alpha-methyldopahydrazine
8. L-alpha-methyldopahydrazine
9. N-aminomethyldopa
10. Carbidopum
11. Carbidopum [inn-latin]
12. Carbidopa (anhydrous)
13. S(-)-carbidopa
14. Mk 486
15. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid
16. Carbidopa [inn]
17. L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic Acid
18. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic Acid
19. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid
20. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid
21. Kr87b45rgh
22. (alphas)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic Acid
23. Chebi:39585
24. 28860-95-9 (anhydrous)
25. Ncgc00024596-05
26. Hadrazino-alpha-methyldopa
27. C-dopa
28. 3,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic Acid
29. Smr000058235
30. Ccris 5093
31. Sr-01000597655
32. Einecs 249-271-9
33. Unii-kr87b45rgh
34. Benzenepropanoic Acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, (s)-
35. Alpha-hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic Acid
36. L-alpha-methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic Acid
37. L-alpha-methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic Acid
38. Mfcd00069231
39. Nd0611
40. Tocris-0455
41. C-126
42. Dsstox_cid_2735
43. Carbidopa [who-dd]
44. Dsstox_rid_76707
45. Dsstox_gsid_22735
46. Lopac0_000382
47. Schembl35084
48. Mls000069628
49. Mls002207014
50. S-(-)-carbidopa Monohydrate
51. Gtpl5159
52. Carbidopa, L- Anhydrous
53. Carbidopa Anhydrous [mi]
54. Chembl1201236
55. Dtxsid4022735
56. Hms2089b12
57. Hms3266a20
58. Hms3411m13
59. Hms3655g20
60. Hms3675m13
61. Hms3713l10
62. Hms3884m14
63. Hy-b0311
64. Tox21_110910
65. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propanoic Acid
66. Bdbm50418773
67. Nsc751137
68. S1891
69. Zinc19168887
70. Akos015969657
71. Benzenepropanoic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, (s)-
72. Hydrocinnamic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, L-
73. Ac-1676
74. Ccg-204476
75. Db00190
76. Sdccgmls-0072919.p025
77. Mls-0072919
78. Smp1_000057
79. Ncgc00024596-01
80. Ncgc00024596-03
81. Ncgc00024596-06
82. Ncgc00024596-07
83. Ncgc00024596-08
84. As-16862
85. Bc164279
86. Mls-0072919.p013
87. Cas-28860-95-9
88. Eu-0100382
89. Sw199080-2
90. 60c959
91. Ab00441332-05
92. Ab00441332-06
93. Ab00441332_07
94. Ab00441332_08
95. Sr-01000597655-1
96. Sr-01000597655-3
97. Sr-01000597655-5
98. Sr-01000597655-9
99. Brd-k78712176-001-07-5
100. Benzenepropanoic Acid, A-hydrazino-3,4-dihydroxy-a-methyl-
101. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinamic Acid
102. (s)-?-hydrazino-?-methyl-?-(3,4-dihydroxyphenyl)propionic Acid
103. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid
104. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoicacid
105. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic Acid
106. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid Monohydrate
107. Benzenepropanoic Acid, .alpha.-hydrazinyl-3,4-dihydroxy-.alpha.-methyl-, (.alpha.s)-
108. Kinson; 3-(3,4-dihydroxy-phenyl)-2-hydrazino-2-methyl-propionic Acid
109. 1426847-87-1
| Molecular Weight | 226.23 g/mol |
|---|---|
| Molecular Formula | C10H14N2O4 |
| XLogP3 | -2.2 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 226.09535693 g/mol |
| Monoisotopic Mass | 226.09535693 g/mol |
| Topological Polar Surface Area | 116 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 261 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Carbidopa |
| PubMed Health | Carbidopa (By mouth) |
| Drug Classes | Antiparkinsonian |
| Drug Label | Carbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline... |
| Active Ingredient | Carbidopa |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 25mg |
| Market Status | Prescription |
| Company | Amerigen Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Lodosyn |
| PubMed Health | Carbidopa (By mouth) |
| Drug Classes | Antiparkinsonian |
| Drug Label | Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro... |
| Active Ingredient | Carbidopa |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 25mg |
| Market Status | Prescription |
| Company | Aton |
| 3 of 4 | |
|---|---|
| Drug Name | Carbidopa |
| PubMed Health | Carbidopa (By mouth) |
| Drug Classes | Antiparkinsonian |
| Drug Label | Carbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline... |
| Active Ingredient | Carbidopa |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 25mg |
| Market Status | Prescription |
| Company | Amerigen Pharms |
| 4 of 4 | |
|---|---|
| Drug Name | Lodosyn |
| PubMed Health | Carbidopa (By mouth) |
| Drug Classes | Antiparkinsonian |
| Drug Label | Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro... |
| Active Ingredient | Carbidopa |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 25mg |
| Market Status | Prescription |
| Company | Aton |
Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication. The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting. The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage. As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.
FDA Label
When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Aromatic Amino Acid Decarboxylase Inhibitors
Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. (See all compounds classified as Aromatic Amino Acid Decarboxylase Inhibitors.)
Dopamine Agents
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)
Absorption
When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.
Route of Elimination
In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.
Volume of Distribution
The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.
Clearance
The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.
The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).
The reported half-life of carbidopa is of approximately 107 minutes.
Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 10MG;100MG
USFDA APPLICATION NUMBER - 17555
DOSAGE - TABLET;ORAL - 25MG;100MG
USFDA APPLICATION NUMBER - 17555
DOSAGE - TABLET;ORAL - 25MG;250MG
USFDA APPLICATION NUMBER - 17555
DOSAGE - TABLET;ORAL - 25MG
USFDA APPLICATION NUMBER - 17830
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 25MG...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 25MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19856
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 50MG...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 50MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19856
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 23....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 23.75MG;95MG
USFDA APPLICATION NUMBER - 203312
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 36....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 36.25MG;145MG
USFDA APPLICATION NUMBER - 203312
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 48....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 48.75MG;195MG
USFDA APPLICATION NUMBER - 203312
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 61....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 61.25MG;245MG
USFDA APPLICATION NUMBER - 203312
DOSAGE - TABLET;ORAL - 12.5MG;200MG;50MG
USFDA APPLICATION NUMBER - 21485
DOSAGE - TABLET;ORAL - 18.75MG;200MG;75MG
USFDA APPLICATION NUMBER - 21485
DOSAGE - TABLET;ORAL - 25MG;200MG;100MG
USFDA APPLICATION NUMBER - 21485
DOSAGE - TABLET;ORAL - 31.25MG;200MG;125MG
USFDA APPLICATION NUMBER - 21485
DOSAGE - TABLET;ORAL - 37.5MG;200MG;150MG
USFDA APPLICATION NUMBER - 21485
DOSAGE - TABLET;ORAL - 50MG;200MG;200MG
USFDA APPLICATION NUMBER - 21485
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Capital Farma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vertellus
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Disintegrants & Superdisintegrants
Controlled & Modified Release
Direct Compression
Solubilizers
Thickeners and Stabilizers
Granulation
Taste Masking
Film Formers & Plasticizers
Co-Processed Excipients
Chewable & Orodispersible Aids
Parenteral
Lubricants & Glidants
Topical
Rheology Modifiers
API Stability Enhancers
Emulsifying Agents
Coloring Agents
Empty Capsules
Vegetarian Capsules
Surfactant & Foaming Agents
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
64
PharmaCompass offers a list of Carbidopa API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Carbidopa manufacturer or Carbidopa supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carbidopa manufacturer or Carbidopa supplier.
PharmaCompass also assists you with knowing the Carbidopa API Price utilized in the formulation of products. Carbidopa API Price is not always fixed or binding as the Carbidopa Price is obtained through a variety of data sources. The Carbidopa Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A STALEVO 200 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of STALEVO 200, including repackagers and relabelers. The FDA regulates STALEVO 200 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. STALEVO 200 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of STALEVO 200 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A STALEVO 200 supplier is an individual or a company that provides STALEVO 200 active pharmaceutical ingredient (API) or STALEVO 200 finished formulations upon request. The STALEVO 200 suppliers may include STALEVO 200 API manufacturers, exporters, distributors and traders.
click here to find a list of STALEVO 200 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A STALEVO 200 DMF (Drug Master File) is a document detailing the whole manufacturing process of STALEVO 200 active pharmaceutical ingredient (API) in detail. Different forms of STALEVO 200 DMFs exist exist since differing nations have different regulations, such as STALEVO 200 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A STALEVO 200 DMF submitted to regulatory agencies in the US is known as a USDMF. STALEVO 200 USDMF includes data on STALEVO 200's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The STALEVO 200 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of STALEVO 200 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The STALEVO 200 Drug Master File in Japan (STALEVO 200 JDMF) empowers STALEVO 200 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the STALEVO 200 JDMF during the approval evaluation for pharmaceutical products. At the time of STALEVO 200 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of STALEVO 200 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a STALEVO 200 Drug Master File in Korea (STALEVO 200 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of STALEVO 200. The MFDS reviews the STALEVO 200 KDMF as part of the drug registration process and uses the information provided in the STALEVO 200 KDMF to evaluate the safety and efficacy of the drug.
After submitting a STALEVO 200 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their STALEVO 200 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of STALEVO 200 suppliers with KDMF on PharmaCompass.
A STALEVO 200 CEP of the European Pharmacopoeia monograph is often referred to as a STALEVO 200 Certificate of Suitability (COS). The purpose of a STALEVO 200 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of STALEVO 200 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of STALEVO 200 to their clients by showing that a STALEVO 200 CEP has been issued for it. The manufacturer submits a STALEVO 200 CEP (COS) as part of the market authorization procedure, and it takes on the role of a STALEVO 200 CEP holder for the record. Additionally, the data presented in the STALEVO 200 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the STALEVO 200 DMF.
A STALEVO 200 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. STALEVO 200 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of STALEVO 200 suppliers with CEP (COS) on PharmaCompass.
A STALEVO 200 written confirmation (STALEVO 200 WC) is an official document issued by a regulatory agency to a STALEVO 200 manufacturer, verifying that the manufacturing facility of a STALEVO 200 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting STALEVO 200 APIs or STALEVO 200 finished pharmaceutical products to another nation, regulatory agencies frequently require a STALEVO 200 WC (written confirmation) as part of the regulatory process.
click here to find a list of STALEVO 200 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing STALEVO 200 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for STALEVO 200 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture STALEVO 200 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain STALEVO 200 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a STALEVO 200 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of STALEVO 200 suppliers with NDC on PharmaCompass.
STALEVO 200 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of STALEVO 200 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right STALEVO 200 GMP manufacturer or STALEVO 200 GMP API supplier for your needs.
A STALEVO 200 CoA (Certificate of Analysis) is a formal document that attests to STALEVO 200's compliance with STALEVO 200 specifications and serves as a tool for batch-level quality control.
STALEVO 200 CoA mostly includes findings from lab analyses of a specific batch. For each STALEVO 200 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
STALEVO 200 may be tested according to a variety of international standards, such as European Pharmacopoeia (STALEVO 200 EP), STALEVO 200 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (STALEVO 200 USP).
